SEC Form SC 13G/A filed by PhaseBio Pharmaceuticals Inc. (Amendment)

7/19/22 11:30:16 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PHAS alert in real time by email

SC 13G/A 1 13G719PHAS.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ___)* PhaseBio Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 717224109 (CUSIP Number) 7/12/2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [_] Rule 13d-1(c) [x_] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13G CUSIP No. 89532M101 1 Names of Reporting Persons MAI Capital Management, LLC 2 Check the appropriate box if a member of a Group (see instructions) (a) [ ] (b) [ ] 3 Sec Use Only 4 Citizenship or Place of Organization United States Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 1,806,679 6 Shared Voting Power 0 7 Sole Dispositive Power 2,675,376 8 Shared Dispositive Power 0 9 Aggregate Amount Beneficially Owned by Each Reporting Person 2,675,376 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) [ ] 11 Percent of class represented by amount in row (9) 5.80% 12 Type of Reporting Person (See Instructions) Item 1. (a) Name of Issuer: PhaseBio Pharmaceuticals Inc (b) Address of Issuers Principal Executive Offices: 1 Great Valley Parkway, Suite 30, Malvern, Pennsylvania 19355 Item 2. (a) Name of Person Filing: MAI Capital Management, LLC (b) Address of Principal Business Office or, if None, Residence: 6050 Oak Tree Blvd Suite 500 Independence, OH 44131 (c) Citizenship: United States (d) Title and Class of Securities: Common (e) CUSIP No.: 717224109 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [_] Broker or dealer registered under Section 15 of the Act; (b) [_] Bank as defined in Section 3(a)(6) of the Act; (c) [_] Insurance company as defined in Section 3(a)(19) of the Act; (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940; (e) [x_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; (j) [_] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); (k) [_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ Item 4. Ownership (a) Amount Beneficially Owned: (b) Percent of Class: 5.80% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 1,806,679 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 2,675,376 (iv) Shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. Item 6. Ownership of more than Five Percent on Behalf of Another Person. Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. Item 8. Identification and classification of members of the group. Item 9. Notice of Dissolution of Group. Item 10. Certifications. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: Holly Cavalier Chief Compliance Officer The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

Get the next $PHAS alert in real time by email

Date

Price Target

Rating

Analyst

9/28/2022

$15.00 → $1.00

Buy → Hold

Stifel

10/13/2021

$15.00

Buy

Stifel

SEC Form SC 13G/A filed by PhaseBio Pharmaceuticals Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for
$PHAS

$PHAS
Press Releases

Fastest customizable press release news feed in the world

PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code

PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights

PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

$PHAS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Van Den Broek Richard

SEC Form 4 filed by Thorp Clay

SEC Form 4 filed by Humphries William D.

$PHAS
Financials

Live finance-specific insights

PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab

PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding

PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting

$PHAS
Large Ownership Changes

This live feed shows all institutional transactions in real time.